Ciltacabtagene autoleucel

Latest news

Tag

Rapid Peak Cilta-Cel Expansion Predicts Delayed Neurotoxicity in Relapsed/Refractory Multiple Myeloma: Clinical and Translational Insights

Rapid and excessive expansion of ciltacabtagene autoleucel (cilta-cel) CAR T-cells associates with delayed neurotoxicity in relapsed/refractory multiple myeloma, with absolute lymphocyte count serving as a practical biomarker to guide early

Oct 29, 2026

Hematology-Oncology

Real-World Impact of Cilta-cel versus Ide-cel in CAR T-Cell Therapy for Multiple Myeloma: Insights from the German DRST Registry

A registry analysis in Germany reveals superior remission conversion and progression-free survival with ciltacabtagene autoleucel compared to idecabtagene vicleucel in heavily pretreated multiple myeloma, supporting individualized CAR T the

Oct 14, 2025

Clinical Updates

Potential Curative Impact of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Five-Year Outcomes from CARTITUDE-1

CARTITUDE-1 demonstrates that a single infusion of ciltacabtagene autoleucel (cilta-cel) yields durable ≥5-year remission and extended survival in heavily pretreated relapsed/refractory multiple myeloma, with compelling MRD negativity and a

Sep 9, 2025